AstraZeneca Stock News

AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market.

The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.

AstraZeneca has become the latest major drugmaker to scale back investment in the United Kingdom, pausing a planned £200 million ($271 million) expansion of its Cambridge research site. The move, which would have created up to 1,000 jobs, highlights growing tensions between the pharmaceutical industry and the UK government over drug pricing and competitiveness.

Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.

AstraZeneca PLC (LSE:AZN) may have caught the market's attention last weekend with promising data on its experimental blood pressure treatment, but the follow-up analysis suggests the story is far from settled. The focus is now shifting to whether the drug can show benefits beyond the clinic chair.

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the foreseeable future. AstraZeneca's net debt to EBITDA ratio has modestly improved so far in 2025, making an already vigorous balance sheet even stronger.

Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrostat, works